Edgar Filing: RIGEL PHARMACEUTICALS INC - Form 4

RIGEL PHAR Form 4 May 24, 2012	MACEUTICA	LS INC								
FORM Check this b if no longer subject to Section 16. Form 4 or	STATEN	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						OMB Number: Expires: Estimated burden hou	Number: 3235-028	
Form 5 obligations may continu <i>See</i> Instruct 1(b).	e. Section 17	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								
(Print or Type Res	ponses)									
1. Name and Address of Reporting Person <u>*</u> RENTON HOLLINGS			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
			3. Date of Earliest Transaction(Month/Day/Year)05/23/2012			X_ Director10% Owner Officer (give titleOther (specify below) below)				
SOUTH SAN	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			ıl	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
FRANCISCO	, CA 94080						Person			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed o	of, or Beneficia	lly Owned	
	Transaction Date Ionth/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report	on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly of	or indirectly.			
					inforr requi	nation cont red to respo	spond to the collect tained in this form ond unless the for ntly valid OMB con	are not m	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	cution Date, if TransactiorDerivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 E S (1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 7.6	05/23/2012		A	15,000	<u>(1)</u>	05/23/2022	Common Stock	15,000	

Edgar Filing: RIGEL PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships					
reporting of the relation of the	Director	10% Owner	Officer	Other			
RENTON HOLLINGS C/O RIGEL PHARMACEUTICALS, IN 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	IC. X						
Signatures							
/s/ Dolly Vance (Attorney-In-Fact)	05/24/2012						
**Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly for twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.